Growing Racial/Ethnic Disparities in Buprenorphine Distribution in the United States, 2007–2017

Published in: Drug and Alcohol Dependence, Volume 223 (June 2021). doi: 10.1016/j.drugalcdep.2021.108710

Posted on RAND.org on April 27, 2021

by Megan S. Schuler, Andrew W. Dick, Bradley D. Stein

Read More

Access further information on this document at Drug and Alcohol Dependence

This article was published outside of RAND. The full text of the article can be found at the link above.

Objective

To assess whether per capita buprenorphine distribution varies by regional racial/ethnic composition, Medicaid expansion status, and time period.

Methods

Our unit of analysis—three-digit ZIP codes ("ZIP3s")—was classified into quintiles based on percentage of White residents. A weighted linear regression model of buprenorphine distribution—including White resident quintile, waivered prescriber rate, overdose rate, sociodemographic factors, and year fixed effects—was estimated using national buprenorphine distribution data from 2007 to 2017. We report predictive margins of the buprenorphine distribution rate by quintile, as well as average marginal effects of waivered prescriber rate on buprenorphine distribution rate for each quintile. Analyses were stratified by Medicaid expansion status and time period (2007–2010, 2011–2014, 2015–2017).

Results

Buprenorphine distribution increased nationally during 2007–2017, yet growth was disproportionately greater for ZIP3s with higher percentages of White residents. Medicaid expansion states exhibited significant differences in buprenorphine distribution across ZIP3 quintiles during 2007–2010, the magnitude of which increased across time periods. Non-expansion states exhibited significant quintile differences during 2011–2014 and 2015–2017. The average marginal effect of increasing the waivered prescriber rate on the distribution rate was consistently smaller in ZIP3s with lower percentages of White residents, particularly in expansion states.

Conclusions

We find ecological evidence consistent with racial/ethnic disparities in buprenorphine distribution. Our finding that increasing the waivered prescriber rate had differential effects by ZIP3 racial/ethnic composition suggest that broad initiatives to increase the number of waivered prescribers are likely insufficient to achieve equitable buprenorphine access. Rather, targeted and tailored policy efforts are warranted.

Research conducted by

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit www.rand.org/about/principles.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.